Researchers conducted a Phase 3 clinical trial involving 549 children between the ages of 3 and 7. These children were newly diagnosed with standard-risk medulloblastoma and had already undergone surgery. The study compared two different radiation methods to see how they affected patient outcomes.
The first group received a reduced-dose craniospinal radiation of 18.00 Gy along with a smaller volume boost focused only on the tumor bed. The second group received the standard-dose craniospinal radiation of 23.40 Gy and a larger volume boost covering the whole posterior fossa.
While the study tracked primary outcomes like event-free survival and overall survival, specific results for these metrics were not reported in the data provided. The trial also monitored secondary factors such as cognitive, auditory, and endocrinologic effects to see how smaller radiation volumes might impact long-term health. Because this is a complex clinical trial, patients should talk to their doctors about how these findings apply to specific treatment plans.
